Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Docetaxel · Beizray, Docivyx

Small molecule · Inhibitor of Tubulin (TUBB) · developed by Sanofi Aventis Us

Approved FDA, May 1996

What is Docetaxel?

Docetaxel is a microtubule inhibitor that binds free tubulin and promotes its assembly into stable microtubules while inhibiting their disassembly, arresting mitosis in cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Beizray, Docivyx, Taxotere, RP-56976, XRP6976
Drug type
Small molecule
Targets
Tubulin (TUBB)
Mechanism
Inhibitor of Tubulin (TUBB)
Pathways
Microtubule assembly and stabilization, Mitotic inhibition
Therapy area
Oncology
Developer
Sanofi Aventis Us
In trials of
MRK, PFE
FDA status
Approved as Beizray, Docivyx, Taxotere (May 14, 1996), NDA020449 · FDA label
UNII
15H5577CQD

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 17, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Carcinoma

Other drugs acting on TUBB

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.